 Tiziana Life Sciences Ltd announced that the US Food and Drugs Administration FDA has accepted its request to enroll a second patient onto the ongoing clinical treatment of secondary progressive multiple sclerosis SPMS. Tiziana, a biotechnology company that enables immunotherapies via novel routes of drug delivery, is evaluating nasally administered foralumab for SPMS. 